TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy

TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy
TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, in an ongoing Phase 1/2 clinical trial for people with advanced cancers that produce the mesothelin protein. Mesothelin is a protein highly abundant in several solid tumors, including ovarian cancer. Its abundance is linked with poorer prognosis, and is suggested to play a role in the development of certain tumors. While CAR T-cell therapy has shown exciting results for treating blood cancers, the response rates in solid cancer have been disappointing. That therapy consists of collecting a patient’s own T-cells and modifying them in the lab to produce a chimeric antigen receptor, or CAR, that targets a specific cancer protein. The CAR T cells are then given back to the patient by infusion. TCR2 Therapeutic’s TC-210 was designed with a new technology, called T-cell Receptor Fusion Constructs, or TRuC-T. It aims to harness the full potential of T-cells against cancer cells. In preclinical studies with cells and animal models of lung, ovarian and mesothelioma cancers, TC-2
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *